Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty

By /

Foresee Pharmaceuticals, announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study.

Scroll to Top